Literature DB >> 24798352

Isolated secondary CNS relapse in a case of stage I diffuse large B-cell lymphoma.

Yana G Najjar1, Kriti Mittal, Nadeen N Faza, Holly Dushkin, David M Peereboom.   

Abstract

A 55-year-old woman was admitted to our hospital with a 10-day history of right arm weakness and numbness. The patient's medical history was notable for lobular carcinoma in situ of the right breast in 2008 and stage I diffuse large B-cell lymphoma of the left axilla. The patient had completed treatment with chemotherapy and radiation 2 months prior to presentation. Blood counts, metabolic panel and lumbar puncture were unremarkable. MRI of the brain revealed multiple enhancing masses. The patient was started on dexamethasone, with rapid symptom improvement. A stereotactic brain biopsy revealed CD20 diffuse large B-cell lymphoma. The patient was started on high-dose intravenous methotrexate. She has received 11 cycles and has regained near normal function of the right arm. The patient's most recent brain MRI showed near complete resolution of all previously seen abnormal foci of enhancement.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24798352      PMCID: PMC4024551          DOI: 10.1136/bcr-2013-201442

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.

Authors:  Michael B Møller; Niels T Pedersen; Bjarne E Christensen
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.

Authors:  N Schmitz; S Zeynalova; B Glass; U Kaiser; E Cavallin-Stahl; M Wolf; M Haenel; M Loeffler; L Truemper; M Pfreundschuh
Journal:  Ann Oncol       Date:  2011-10-11       Impact factor: 32.976

4.  Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.

Authors:  P A Bunn; P S Schein; P M Banks; V T DeVita
Journal:  Blood       Date:  1976-01       Impact factor: 22.113

5.  Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.

Authors:  L Recht; D J Straus; C Cirrincione; H T Thaler; J B Posner
Journal:  Am J Med       Date:  1988-03       Impact factor: 4.965

Review 6.  Secondary central nervous system lymphoma.

Authors:  Naoto Tomita; Fumio Kodama; Heiwa Kanamori; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

Review 7.  Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature.

Authors:  Natalia Colocci; Michael Glantz; Lawrence Recht
Journal:  Semin Neurol       Date:  2004-12       Impact factor: 3.420

8.  Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.

Authors:  P L Zinzani; M Magagnoli; G Frezza; G Prologo; F Gherlinzoni; M Bendandi; P Albertini; L Babini; R D'Alessandro; S Tura
Journal:  Leuk Lymphoma       Date:  1999-02

9.  Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.

Authors:  Jack Phan; Ali Mazloom; L Jeffrey Medeiros; Tony G Zreik; Christine Wogan; Ferial Shihadeh; Maria Alma Rodriguez; Luis Fayad; Nathan Fowler; Valerie Reed; Patrecia Horace; Bouthaina Shbib Dabaja
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

Review 10.  Central nervous system lymphoma.

Authors:  Andrew Lister; Lauren E Abrey; John T Sandlund
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.